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In a post hoc analysis of samples from an intrapartum 
azithromycin randomized clinical trial, we found that chil-
dren whose mothers had been treated with the drug had higher 
prevalence of macrolide-resistance genes msr(A) and ermC at 
28 days but not at 12 months. The 2 genes were positively asso-
ciated in the nasopharynx.
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Prophylactic use of azithromycin (AZI) has been investigated 
in low- and middle-income countries as an intervention to de-
crease infant mortality [1].
In a recent double-blinded, placebo-controlled trial con-
ducted in The Gambia (PregnAnZI), a single dose of oral 
AZI (2 g) was administered during labor to assess the impact 
on bacterial colonization of gram-positive bacterial species 
(Staphylococcus aureus, Streptococcus pneumoniae, and group 
B Streptococcus) in both mothers and their offspring. The trial 
showed that this intervention reduced bacterial colonization 
in women and infants during the 4 weeks after birth but in-
creased the prevalence of AZI-resistant S. aureus, although in 
a follow-up study of the trial participants it was observed that 
carriage of AZI-resistant S. aureus strains had waned by the age 
of 12 months [2].
Molecular analysis of the AZI-resistant S. aureus strains iso-
lated in the PregnAnZI trial revealed that the predominant 
genetic determinants responsible for macrolide resistance in 
this population were macrolide and streptogramin A resist-
ance msr(A) and erythromycin ribosomal methylase C (ermC) 
[3]. Both these genes are carried by mobile genetic elements; 
hence, horizontal spread between bacteria colonizing the same 
ecological niche could take place through transformation, con-
jugation, or transfection [4–6]. In fact, msr(A) and ermC are 
also present in other bacteria that colonize the nasopharynx 
such as Staphylococcus species and Enterococcus species [7–11]. 
Consequently, screening a single bacterium (ie, S. aureus) may 
underestimate the true prevalence for resistance. The aim of this 
post hoc study was to evaluate the effect of intrapartum AZI 
on the prevalence of the macrolide-resistance genes [msr(A) 
and ermC] in the nasopharynx at different time points during 
infancy.
METHODS
The PregnAnZI trial was a phase III, double-blind, placebo-
controlled trial in which 829 pregnant women attending the 
maternity ward were randomized to receive either a single oral 
dose (2  g) of intrapartum AZI or placebo (ratio of 1:1). The 
study protocol has been described elsewhere [12]. After com-
pletion of the trial, nasopharyngeal swab (NPS) were collected 
in a follow-up survey done when the children were between 11 
and 13 months of age. Ethical approval was obtained for both 
the main trial and the 12-month survey. Women had signed 
consent during antenatal visits and signed another consent for 
the infant’s follow-up visit.
Only children from whom NPS were collected at birth (day 
0), day 28, and at 12 months were eligible for inclusion in this 
post hoc study. The study was conducted using 936 samples 
from 312 children (n = 155 AZI arm and n = 157 placebo arm) 
who were selected at random from among the eligible children 
(n = 426).
Genomic DNA was extracted directly from NPS using the 
QIAamp DNA Mini Kit (Qiagen, United Kingdom) protocol 
with some modifications. The DNA was eluted in 100-µL 
volume and stored at −20ºC.
The primers for the amplification of the macrolide resistance 
genes [msr(A)_F ATCCAATCATTGCACAAAATCTAACATT, 
msr(A)_R TAAATAGCTTCAAGTAAAGTTGTCTTACC and 
ermC_F CTTGTTGATCACGATAATTTCCAAG, ermC_R 
TTGTATTCTTTGTTAACCCATTTCATAAC] were designed 
using Primer 3 and synthesized by Metabion, Germany. The 
BRIEF REPORT • cid 2020:71 (15 december) • 3223
cycling conditions included an initial denaturation at 98ºC for 
30 seconds, 35 cycles of denaturation at 98ºC for 5 seconds, 
annealing at 52ºC for 5 seconds, and extension at 72ºC for 
10 seconds, with a final extension at 72ºC for 1 minute. Fully 
sequenced S. aureus carrying either the ermC or msr(A) genes 
were used as positive controls.
Polymerase chain reaction (PCR) analyses were performed 
alongside DNA extract from a pure S.  aureus isolate known 
to carry either the ermC or msr(A) gene (positive controls) 
[3]. The PCR products were analyzed using QIAxcel advanced 
Screen gel 1.5.0 (Qiagen) [13] with a tolerance rate of  ±15% 
of the expected band size [msr(A) 145 bp and ermC 398 bp]. 
Samples were categorized as being either positive or negative for 
each resistance gene.
Pearson’s χ 2 test was used to compare the prevalence of 
macrolide-resistance genes between arms at birth, day 28, and 
at 12 months. The χ 2 test was also used to test for an associa-
tion between the resistance genes at day 28. This analysis was 
further stratified by trial arm, and a Mantel-Haenszel test for 
interaction was done to test whether the strength of association 
varied between arms. A P value ≤ .05 was used as the cutoff for 
statistical significance. All analyses were carried out using Stata 
version 12.1 software (StataCorp).
RESULTS
Study Population and Samples
Baseline characteristics of the study mothers (maternal age at 
delivery, fundal height, mode of delivery, ethnicity, and season 
of birth) and their infants (sex, birth weight, and Apgar score) 
selected for this post hoc study were comparable between the 
AZI and placebo arms (see Supplementary Table 1).
Prevalence of Macrolide-resistance [Msr(A) and ErmC] Genes in Infants
The prevalence of msr(A) at birth was similar between trial arms 
(25.2% vs 25.5% in the AZI and placebo arms, respectively). At 
day 28, the prevalence was higher among children in the AZI 
arm (60.7% vs 29.9%; odds ratio [OR], 3.61; 95% confidence 
interval [CI], 2.20–5.93]), but the difference had waned by the 
age of 12 months (see Table 1).
The prevalence of ermC was also similar between trial arms at 
birth (30% vs 35.0% in the AZI and placebo arms, respectively). 
As with msr(A), the gene was more common among children 
in the AZI arm at day 28 (63.9% vs 45.9%; OR, 2.09; 95% CI, 
1.29–3.37) and the difference was no longer significant by the 
age of 12 months (see Table 1).
Association of msr(A) and ermC Genes at Day 28
At day 28, there was a positive association between the ermC 
and msr(A) genes (OR, 2.31; 95% CI, 1.42–3.76). Although the 
association appeared to be stronger in samples from the placebo 
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1.41; 95% CI, .68–2.90), there was no evidence of an interaction 
by study arm (P = .162).
DISCUSSION
Our analysis shows that although intrapartum AZI increases carriage 
of macrolide-resistance genes [msr(A) and ermC] in the first month 
of life, and the increase is not sustained by 1 year. This short-term in-
crease in genetic mediators of resistance mirrors the pattern of pheno-
typic resistance for S. aureus that has previously been reported [2, 14].
Data on msr(A) and ermC gene prevalence following pro-
phylactic AZI are scarce. In The Gambia, cases of AZI-resistant 
S. aureus from all age groups in the community following mass 
drug administration with AZI were attributed to the pres-
ence of either msr or erm(C) genes [15]. A study conducted in 
Australia and New Zealand found a nonsignificant increase in 
carriage of msr(A) in patients with non–cystic fibrosis bron-
chiectasis on long-term erythromycin, a sister macrolide to 
AZI [16]. Another study conducted in children under 5 years 
in Niger found that children who received twice-a-year AZI 
had an approximately 30% higher prevalence of the strepto-
coccal macrolide-resistance determinant mefA/E, an equivalent 
of the staphylococcal msr(A) gene, than did children who re-
ceived AZI once per year [17]. Although formal comparisons 
between the aforementioned trial and our trial are difficult 
because of the different designs (community seasonal prophy-
laxis vs single-dose intrapartum administration), it appears that 
mefA/E persisted longer within the population than msr(A) or 
ermC. We did not include mefA/E in our study as the gene is 
predominantly associated with Streptococci, and in our trial AZI 
resistance following intrapartum oral intervention was only sig-
nificantly increased for S. aureus and not S. pneumoniae [2, 14].
The increase in ermC or msr(A) prevalence observed at day 
28 is associated with increased macrolide resistance in the 
study population. The presence of the msrA gene is indicative 
of phenotypic resistance to 14-membered (clarithromycin, 
dirithromycin, and erythromycin) or 15-membered (AZI) 
macrolides as well as streptogramin A but sensitive to 16-mem-
bered ring macrolides. On the other hand, the presence of the 
ermC gene is also associated with an even wider scope of phe-
notypic resistance, including resistance to clindamycin and 
streptogramin B, depending on whether the presence of the 
gene results in an inducible or constitutive phenotype [18]. All 
S. aureus isolates carrying ermC from our previous molecular 
and phenotypic analysis showed constitutive resistance [2]. 
Like the msr(A) gene, the prevalence of ermC at 12  months 
was nonsignificantly higher in the AZI arm than in the placebo 
arm. However, additional studies should determine whether the 
ermC gene, beyond being as prevalent as msr(A), is also more 
persistent as its prevalence in the AZI arm was 51.6% compared 
with 17.4% for the msr(A) gene at 12 months.
In our previous molecular analysis of S. aureus isolates, we 
observed a negative association between ermC and msr(A) [3]. 
In contrast, the current analysis identified a positive associa-
tion between the 2 genes. Taken together, these results suggest 
that macrolide-resistance genes tend to co-occur in the same 
sample but are carried by different bacterial isolates or species. 
Staphylococcus epidermidis, for example, has been reported to 
carry both ermC and msr(A) genes [11].
Key limitations of the study include that it was not possible 
to (1) determine for how long beyond 28 days AZI resistance 
was maintained, (2) relate the prevalence of the macrolide-
resistance genes to changes in microbiome diversity, and (3) 
ascertain whether the msr(A) and ermC genes detected by PCR 
were functional.
In conclusion, screening for macrolide-resistance genes fol-
lowing intrapartum AZI exposure revealed increased preva-
lence of both msr(A) and ermC during the neonatal period but 
not at 12 months of age. Genetic surveillance should be used to 
complement conventional antimicrobial resistance surveillance 
in the event prophylactic AZI interventions are rolled out in 
The Gambia or elsewhere.
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